9 completed, 6 terminated, 5 recruiting, 2 active not recruiting. 26 Phase 1, 9 Phase 2.
Follow Hepatocellular Cancer: new trials by email Literature Review of Hepatocellular Cancer trials Research Report on Hepatocellular Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. PF-08634404, Ipilimumab - Carcinoma, Hepatocellular, Hepatocellular Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 138 | 2025-12-01 | 2026-10-08 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) Lenvatinib, ABBV-324 - Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 232 | 2025-04-14 | 2026-09-22 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC Durvalumab, Tremelimumab, SIRT - Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 1 | Active not recruiting | Jiping Wang, MD, PhD | 20 | 2023-04-21 | 2026-08-13 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Q702, Pembrolizumab - Esophageal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Qurient Co., Ltd. | 120 | 2023-01-12 | 2026-02-24 |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor | Phase 1 / Phase 2 | Terminated | Omega Therapeutics | 24 | 2022-08-19 | 2025-02-03 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors vobramitamab duocarmazine, lorigerlimab - Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | Phase 1 | Completed | MacroGenics | 31 | 2022-04-19 | 2025-10-14 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies Cyclophosphamide, CAR-T cell, Fludarabine - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 38 | 2021-12-08 | 2026-10-16 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors PF-07263689, Sasanlimab - Renal Cell Cancer, Melanoma | Phase 1 | Terminated | Pfizer | 13 | 2021-10-20 | 2024-04-12 |
| Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine - Melanoma, Colon Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2018-05-18 | 2020-06-02 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers TTI-101 - Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Completed | Tvardi Therapeutics, Incorporated | 64 | 2017-11-15 | 2025-03-21 |
| AFPᶜ³³²T in Advanced HCC Autologous genetically modified AFPᶜ³³²T cells - Hepatocellular Cancer, AFP Expressing Tumors | Phase 1 | Completed | Adaptimmune | 39 | 2017-05-08 | 2026-06-17 |
| Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. NIS793, PDR001 - Breast Cancer, Lung Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 120 | 2017-04-25 | 2022-01-31 |
| Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer Trametinib, Sorafenib - Hepatocellular Cancer, Liver Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2015-02-18 | 2021-06-10 |
| Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Sorafenib, yttrium-90 radioembolization - Hepatocellular Cancer | Phase 1 | Withdrawn | University of Hawaii | 2014-11-01 | 2019-11-08 | |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Emibetuzumab, Ramucirumab - Advanced Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 97 | 2014-03-07 | 2020-12-19 |
| Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm OXY111A - Pancreatic Neoplasms, Hepatocellular Cancer | Phase 1 / Phase 2 | Unknown | University of Zurich | 69 | 2014-02-01 | 2015-08-19 |
| Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer OMP-54F28 with Sorafenib - Hepatocellular Cancer, Liver Cancer | Phase 1 | Completed | OncoMed Pharmaceuticals, Inc. | 10 | 2014-01-01 | 2020-08-11 |
Showing 20 of 26. Sign in to see all of them.
Liver Neoplasms (26) · Carcinoma, Hepatocellular (7) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (6) · Pancreatic Neoplasms (6) · Colorectal Neoplasms (5) · Kidney Neoplasms (5) · Melanoma (5) · Carcinoma, Renal Cell (4) · Colonic Neoplasms (4) · Esophageal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Cholangiocarcinoma (2)
Digestive System Neoplasms (26) · Neoplasms by Site (26) · Digestive System Diseases (25) · Liver Diseases (25) · Neoplasms (24) · Neoplasms by Histologic Type (17) · Neoplasms, Glandular and Epithelial (15) · Carcinoma (13) · Adenocarcinoma (12) · Gastrointestinal Diseases (11) · Urogenital Diseases (11) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Gastrointestinal Neoplasms (10) · Male Urogenital Diseases (10)
Sorafenib (5) · Ipilimumab (2) · pembrolizumab (2) · C188-9 compound (1) · Cyclophosphamide (1) · Dexamethasone (1) · Enkephalin, Methionine (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy, Adoptive (1) · NIS-793 (1) · National Cancer Institute (U.S.) (1) · Nivolumab (1) · OMP-54F28 (1) · Radiotherapy (1) · Ramucirumab (1)
National Cancer Institute (NCI) (2) · Pfizer (2) · 7 Hills Pharma, LLC (1) · AbbVie (1) · Adaptimmune (1) · Columbia University (1) · Eli Lilly and Company (1) · Envita Medical Center, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jiping Wang, MD, PhD (1) · Lisa H. Butterfield, Ph.D. (1) · MacroGenics (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · ModeX Therapeutics, An OPKO Health Company (1)
United States (25) · Taiwan (4) · Japan (3) · China (2) · Hong Kong (2) · Puerto Rico (2) · South Korea (2) · Spain (2) · Switzerland (2) · Austria (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1)
Abby Siegel, MD, MS (1) · Apostolia Tsimberidou, MD, PhD (1) · Arkaduisz Z Dudek, MD (1) · Beth A. Erickson-Wittmann, M.D. (1) · David Korn, D.O., M.D. (1) · Denise Casey, M.D. (1) · Eric T Kimchi, MD (1) · James Pingpank, MD (1) · Jared Acoba, MD (1) · Jiping Wang, MD, PhD (1) · Lionel Lewis, MA, MB.Bch, MD (1)
PMID 27756258, PMID 30832732, PMID 32776632, PMID 33016924, PMID 34155211, PMID 38030303, PMID 39792482, PMID 40812667, PMID 41495607
2016 (1), 2017 (1), 2025 (1), R01CA104524 (1)